Duloxetine vs placebo in the treatment of stress urinary incontinence: A four-continent randomized clinical trial

BJU International

Volumn 93, Issue 3, 2004, Pages 311-318

  Millard, R J ^a   Moore, K ^b   Rencken, R ^c   Yalcin, I ^d   Bump, R C ^d  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b ST GEORGE HOSPITAL   (Australia)

^c St Anne Hospital   (South Africa)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Duloxetine hydrochloride; Noradrenaline; Quality of life; Serotonin; Stress urinary incontinence

Indexed keywords

DULOXETINE; PLACEBO;

ADULT; ADVERSE DRUG REACTION; AGED; ALGORITHM; ANALYSIS OF VARIANCE; ANOREXIA; ANXIETY DISORDER; ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; FATIGUE; FEMALE; GEOGRAPHY; HEADACHE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; STRESS INCONTINENCE; SWEATING; VOMITING; XEROSTOMIA;

EID: 1342310038     PISSN: 14644096     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2004.04607.x     Document Type: Article

References (23)

1. Hampel C, Wienhold D, Benken N, Eggersmann C, Thüroff J. Definition of overactive bladder and epidemiology of urinary incontinence. Urology 1997; 50 (Suppl 6A): 4-14
2. Abrams P, Cardozo L, Fall M et al. The standardisation of terminology of lower urinary tract function: report from the standardistion sub-committee of the International Continence Society. Neurourol Urodyn 2002; 21: 167-78
3. US Bureau of the Census. Report WP/98, World Population Profile: 1998. Washington, DC: USA Government Printing Office, 1999
4. Espey MJ, Du H-J, Downie JW. Serotonergic modulation of spinal ascending activity and sacral reflex activity evoked by pelvic nerve stimulation in cats. Brain Res 1998; 798: 101-8
5. Thor KB, Hisamitsu T, de Groat WC. Unmasking of a neonatal somatovesical reflex in adult cats by the serotonin autoreceptor agonist 5-methoxy-N,N- dimethyltryptamine. Brain Res Dev Brain Res 1990; 54: 35-42
6. Danuser H, Thor KB. Spinal 5-HT2 receptor-mediated facilitation of pudendal nerve reflexes in the anaesthetized cat. Br J Pharmacol 1996; 118: 150-4
7. Krier J, Thor KB, de Groat WC. Effects of clonidine on the lumbar sympathetic pathways to the large intestine and urinary bladder of the cat. Eur J Pharmacol 1979; 59: 47-53
8. Pedersen E, Torring J, Klemar B. Effect of the alpha-adrenergic blocking agent thymoxamine on the neurogenic bladder and urethra. Acta Neurol Scand 1980; 61: 107-14
9. Gajewski J, Downie JW, Awad SA. Experimental evidence for a central nervous system site of action in the effect of alpha-adrenergic blockers on the external urinary sphincter. J Urol 1984; 132: 403-9
10. Downie JW, Bialik GJ. Evidence for a spinal site of action of clonidine on somatic and viscerosomatic reflex activity evoked on the pudendal nerve in cats. J Pharmacol Exp Ther 1988; 246: 352-8
11. Downie JW, Espey MJ, Gajewski JB. Alpha 2-adrenoceptors not imidazole receptors mediate depression of a sacral spinal reflex in the cat. Eur J Pharmacol 1991; 195: 301-4
12. Espey MJ, Downie JW, Fine A. Effect of 5-HT receptor and adrenoceptor antagonists on micturition in conscious cats. Eur J Pharmacol 1992; 221: 167-70
13. Bymaster FP, Dreshfield-Ahmad LJ, Threlkeld PG et al. Comparative affinity of duloxetine and venlafaxine for serotonin and norepinephrine transporters in vitro and in vivo, human serotonin receptor subtypes, and other neuronal receptors. Neuropsychopharmacology 2001; 25: 871-80
14. Thor KB, Katofiasc MA. Effects of duloxetine, a combined serotonin and norepinephrine reuptake inhibitor, on central neural control of lower urinary tract function in the chloralose-anesthetized female cat. J Pharmacol Exp Ther 1995; 274: 1014-24
15. Katofiasc MA, Nissen J, Audia JE, Thor KB. Comparison of the effects of serotonin selective, norepinephrine selective, and dual serotonin and norepinephrine reuptake inhibitors on lower urinary tract function in cats. Life Sci 2002; 71: 1227-36
16. Norton PA, Zinner NR, Yalcin I, Bump RC. Duloxetine versus placebo in the treatment of stress urinary incontinence. Am J Obstet Gynecol 2002; 187: 40-8
17. Wagner TH, Patrick DL, Bavendam TG, Martin ML, Buesching DP. Quality of life of persons with urinary incontinence: development of a new measure. Urology 1996; 47: 67-71
18. Patrick DL, Martin ML, Bushnell DM, Yalcin I, Wagner TH, Buesching DP. Quality of life of women with urinary incontinence: Further development of the incontinence quality of life instrument (I-QOL). Urology 1999; 53: 71-6
19. Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol 2003; 189: 98-101
20. van Elteren PH. On the combination of independent two-sample tests of Wilcoxon. Bull Int Stat Inst 1960; 37: 1-13
21. Dmochowski RR, Miklos JR, Norton PA et al. Duloxetine vs. placebo in the treatment of North American women with stress urinary incontinence. J Urol 2003; 170: 1259-63
22. Van Kerrebroeck P, Abrams P, Lange R et al. Duloxetine vs. placebo in the treatment of European and Canadian women with stress urinary incontinence. Eur Urol 2003; Suppl 2:29
23. Wong DT, Bymaster FP, Mayle DA, Reid LR, Krushinski JG, Robertson DW. LY248686, a new inhibitor of serotonin and norepinephrine uptake. Neuropsychopharmacol 1993; 8: 23-33